Novartis blockbuster Mayzent wins European nod for multiple sclerosis Medical Dialogues Bureau22 Jan 2020 11:25 AM IST The European marketing authorization makes Mayzent the first and only indicated oral treatment proven in SPMS patients with the active disease based...